CNTX has announced that the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76. This experimental ...

Infineon Technologies has formed a new business unit to drive the company’s growth in the area of sensors by combining the ...

PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced the appointment of Andy Pasternak as Chairman of ...

The gut microbiome, or the community of microorganisms residing in the gastrointestinal tract, has emerged as an important ...

Kanavos Inc, a trailblazer in cannabinoid knowledge graph development, today announced a strategic partnership with Graphwise, a global leader in advanced knowledge graph and semantic AI technologies.

TG Therapeutics' stock rose 15% since my November buy recommendation, driven by Briumvi's strong performance and strategic ...

Amex GBT labeled the DOJ's lawsuit to block its merger with CWT "a blatant politicized effort," which didn't reflect how the ...

The firm will evaluate its CLDN6- and CD3 T-cell-engaging bispecific antibody in advanced or metastatic ovarian, endometrial, and testicular cancers.

Context Therapeutics has dosed the first subject in the Phase I trial of CTIM-76, targeting claudin 6 (CLDN6)-positive ...

CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving pipeline progress PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therap ...

Research presented at SABCS 2024 provided new insights that may influence the management of early and advanced breast cancer.

CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancersTrial marks key milestone in driving pipeline ...